Best Fit Profiles
- experimental senolytic cycles
Senolytic protocols
Fisetin
Preclinical senolytic rationale is strong, while human evidence remains early-stage with limited definitive outcome data.
Evidence Level C
Evidence and Risk Labels
Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.
See full scoring guideClinical Snapshot
- Effect Size
- Translational signal with limited clinical outcome confirmation
- Safety
- Moderate Risk
Long-term human efficacy uncertain.
Research Dosing
This reflects common ranges and protocols used in published studies, not personal medical advice.
- Typical Daily Dose
- 100-500 mg in cycling protocols
- Timing
- Short pulse cycles rather than continuous daily use
- Protocol Duration in Studies
- Intermittent cycles (for example 2-5 days per month)
Human evidence remains limited; cycle design varies widely across experimental protocols.